A recent consensus group has suggested that for selecting breast cancer patients for clinical trials investigating new drugs, an optimal gene panel should detect AKT1, PIK3CA, PTEN, ESR1 mutations and FGFR1 amplification, in addition to the study of ER, PR, HER2 and BRCA1/2 [85]. Here, PIK3CA is linked to breast cancer.